Atlas Trials

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia

Clinical trial NCT01994473 · COMPLETED

Trial details

NCT number
NCT01994473
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Schizophrenia
Start date
2013-10-01
Primary completion
2014-12-01
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.